How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

被引：9
|
作者：
Kunitoh, H.
Suzuki, K.
机构：
[1] Natl Canc Ctr, Dept Internal Med & Thorac Oncol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Thorac Surg, Chuo Ku, Tokyo 1040045, Japan
来源：
BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 10期
关键词：
trimodality; preoperative chemoradiotherapy; stage IIINSCLC; superior sulcus tumour;
D O I：
10.1038/sj.bjc.6603751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.
引用
收藏
页码：1498 / 1503
页数：6
相关论文
共 50 条
  • [21] Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer
    Lo, Ernest
    Daly, Megan E.
    Mack, Philip C.
    Kelly, Karen
    Lara, Primo N., Jr.
    [J]. LUNG CANCER MANAGEMENT, 2013, 2 (01) : 75 - 85
  • [22] NEOADJUVANT AND ADJUVANT THERAPY IN THE MANAGEMENT OF LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER
    JAKLITSCH, MT
    STRAUSS, GM
    SUGARBAKER, DJ
    [J]. WORLD JOURNAL OF SURGERY, 1993, 17 (06) : 729 - 734
  • [23] Targeted therapy in advanced non-small-cell lung cancer
    Gettinger, Scott
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 29 (03) : 291 - 301
  • [24] Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC): Predictors of Surgical Drop Out
    Liriano, M.
    Nichols, E. M.
    Morris, C. G.
    Burrows, W.
    Battafarano, R. J.
    Garofalo, M. C.
    Turner, M.
    Suntharalingam, M.
    Edelman, M. J.
    Feigenberg, S. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S173 - S174
  • [25] Gefitinib therapy for advanced non-small-cell lung cancer
    Liu, CY
    Seen, S
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (11) : 1644 - 1653
  • [26] Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non-small cell lung cancer
    Han, James E.
    Hasan, Shaakir
    Choi, J. Isabelle
    Press, Robert H.
    Simone, Charles B., II
    [J]. CANCER MEDICINE, 2021, 10 (17): : 5794 - 5808
  • [27] Issues in nonoperative management of locally advanced non-small-cell lung cancer
    Curran, WJ
    Werner-Wasik, M
    [J]. ONCOLOGY-NEW YORK, 1998, 12 (01): : 60 - 66
  • [28] Decision analysis in locally advanced non-small-cell lung cancer: Is it useful?
    Brundage, MD
    Groome, PA
    FeldmanStewart, D
    Davidson, JR
    Mackillop, WJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 873 - 883
  • [29] EFFICACY OF CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER
    Almodovar, M.
    Ramos, H.
    Mota, P.
    Martins, V.
    Pereira, P.
    [J]. LUNG CANCER, 2011, 71 : S42 - S43
  • [30] Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer
    Spina, R.
    Chu, S. Y. Y.
    Chatfield, M.
    Chen, J.
    Tin, M. M.
    Boyer, M.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (07) : 790 - 797
12345